These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 23647573)

  • 1. That which does not kill me makes me stronger; combining ERK1/2 pathway inhibitors and BH3 mimetics to kill tumour cells and prevent acquired resistance.
    Sale MJ; Cook SJ
    Br J Pharmacol; 2013 Aug; 169(8):1708-22. PubMed ID: 23647573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The BH3 mimetic ABT-263 synergizes with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM-dependent tumour cell death and inhibit acquired resistance.
    Sale MJ; Cook SJ
    Biochem J; 2013 Mar; 450(2):285-94. PubMed ID: 23234544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.
    Trunzer K; Pavlick AC; Schuchter L; Gonzalez R; McArthur GA; Hutson TE; Moschos SJ; Flaherty KT; Kim KB; Weber JS; Hersey P; Long GV; Lawrence D; Ott PA; Amaravadi RK; Lewis KD; Puzanov I; Lo RS; Koehler A; Kockx M; Spleiss O; Schell-Steven A; Gilbert HN; Cockey L; Bollag G; Lee RJ; Joe AK; Sosman JA; Ribas A
    J Clin Oncol; 2013 May; 31(14):1767-74. PubMed ID: 23569304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib.
    Song H; Zhang J; Ning L; Zhang H; Chen D; Jiao X; Zhang K
    Med Sci Monit; 2018 May; 24():3002-3010. PubMed ID: 29737325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MEK1/2 inhibitor withdrawal reverses acquired resistance driven by BRAF
    Sale MJ; Balmanno K; Saxena J; Ozono E; Wojdyla K; McIntyre RE; Gilley R; Woroniuk A; Howarth KD; Hughes G; Dry JR; Arends MJ; Caro P; Oxley D; Ashton S; Adams DJ; Saez-Rodriguez J; Smith PD; Cook SJ
    Nat Commun; 2019 May; 10(1):2030. PubMed ID: 31048689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumour cell responses to MEK1/2 inhibitors: acquired resistance and pathway remodelling.
    Little AS; Balmanno K; Sale MJ; Smith PD; Cook SJ
    Biochem Soc Trans; 2012 Feb; 40(1):73-8. PubMed ID: 22260668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of BCL2 Family Members Increases the Efficacy of Copper Chelation in BRAF
    Kim YJ; Tsang T; Anderson GR; Posimo JM; Brady DC
    Cancer Res; 2020 Apr; 80(7):1387-1400. PubMed ID: 32005716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.
    Greger JG; Eastman SD; Zhang V; Bleam MR; Hughes AM; Smitheman KN; Dickerson SH; Laquerre SG; Liu L; Gilmer TM
    Mol Cancer Ther; 2012 Apr; 11(4):909-20. PubMed ID: 22389471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model.
    Danysh BP; Rieger EY; Sinha DK; Evers CV; Cote GJ; Cabanillas ME; Hofmann MC
    Oncotarget; 2016 May; 7(21):30907-23. PubMed ID: 27127178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting melanoma's MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors.
    Sale MJ; Minihane E; Monks NR; Gilley R; Richards FM; Schifferli KP; Andersen CL; Davies EJ; Vicente MA; Ozono E; Markovets A; Dry JR; Drew L; Flemington V; Proia T; Jodrell DI; Smith PD; Cook SJ
    Nat Commun; 2019 Nov; 10(1):5167. PubMed ID: 31727888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Control of cell death and mitochondrial fission by ERK1/2 MAP kinase signalling.
    Cook SJ; Stuart K; Gilley R; Sale MJ
    FEBS J; 2017 Dec; 284(24):4177-4195. PubMed ID: 28548464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Copper is required for oncogenic BRAF signalling and tumorigenesis.
    Brady DC; Crowe MS; Turski ML; Hobbs GA; Yao X; Chaikuad A; Knapp S; Xiao K; Campbell SL; Thiele DJ; Counter CM
    Nature; 2014 May; 509(7501):492-6. PubMed ID: 24717435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines.
    Balmanno K; Chell SD; Gillings AS; Hayat S; Cook SJ
    Int J Cancer; 2009 Nov; 125(10):2332-41. PubMed ID: 19637312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells.
    Little AS; Balmanno K; Sale MJ; Newman S; Dry JR; Hampson M; Edwards PA; Smith PD; Cook SJ
    Sci Signal; 2011 Mar; 4(166):ra17. PubMed ID: 21447798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A correction to the research article titled: "Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells" by A. S. Little, K. Balmanno, M. J. Sale, S. Newman, J. R. Dry, M. Hampson, P. A. W. Edwards, P. D. Smith, S. J. Cook.
    Little AS; Balmanno K; Sale MJ; Newman S; Dry JR; Hampson M; Edwards PA; Smith PD; Cook SJ
    Sci Signal; 2011; 4(170):er2. PubMed ID: 21674991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination Treatment with the BRAF
    Jeong JH; Oh JM; Jeong SY; Lee SW; Lee J; Ahn BC
    Thyroid; 2019 Apr; 29(4):540-548. PubMed ID: 30869573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors.
    Basile KJ; Le K; Hartsough EJ; Aplin AE
    Pigment Cell Melanoma Res; 2014 May; 27(3):479-84. PubMed ID: 24422853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma.
    Fofaria NM; Frederick DT; Sullivan RJ; Flaherty KT; Srivastava SK
    Oncotarget; 2015 Dec; 6(38):40535-56. PubMed ID: 26497853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The increase in BIK expression following ERK1/2 pathway inhibition is a consequence of G₁ cell-cycle arrest and not a direct effect on BIK protein stability.
    Sale MJ; Cook SJ
    Biochem J; 2014 May; 459(3):513-24. PubMed ID: 24527759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BCL2 induced by LAMTOR3/MAPK is a druggable target of chemoradioresistance in mesenchymal lung cancer.
    Kwon OS; Hong SK; Kwon SJ; Go YH; Oh E; Cha HJ
    Cancer Lett; 2017 Sep; 403():48-58. PubMed ID: 28606806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.